JP2016519650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519650A5 JP2016519650A5 JP2016500767A JP2016500767A JP2016519650A5 JP 2016519650 A5 JP2016519650 A5 JP 2016519650A5 JP 2016500767 A JP2016500767 A JP 2016500767A JP 2016500767 A JP2016500767 A JP 2016500767A JP 2016519650 A5 JP2016519650 A5 JP 2016519650A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims 41
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 239000012634 fragment Substances 0.000 claims 37
- 101710169781 Gremlin-1 Proteins 0.000 claims 17
- 102100038367 Gremlin-1 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 229920000669 heparin Polymers 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000009116 palliative therapy Methods 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000046318 human GREM1 Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782874P | 2013-03-14 | 2013-03-14 | |
| US61/782,874 | 2013-03-14 | ||
| US201361883218P | 2013-09-27 | 2013-09-27 | |
| US61/883,218 | 2013-09-27 | ||
| PCT/US2014/021471 WO2014159010A1 (en) | 2013-03-14 | 2014-03-07 | Human antibodies to grem 1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087970A Division JP2019151654A (ja) | 2013-03-14 | 2019-05-08 | ヒト抗ｇｒｅｍ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519650A JP2016519650A (ja) | 2016-07-07 |
| JP2016519650A5 true JP2016519650A5 (enExample) | 2017-04-06 |
| JP6581075B2 JP6581075B2 (ja) | 2019-09-25 |
Family
ID=50390267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500767A Active JP6581075B2 (ja) | 2013-03-14 | 2014-03-07 | ヒト抗ｇｒｅｍ１抗体 |
| JP2019087970A Pending JP2019151654A (ja) | 2013-03-14 | 2019-05-08 | ヒト抗ｇｒｅｍ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087970A Pending JP2019151654A (ja) | 2013-03-14 | 2019-05-08 | ヒト抗ｇｒｅｍ１抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10377817B2 (enExample) |
| EP (1) | EP2970448B1 (enExample) |
| JP (2) | JP6581075B2 (enExample) |
| KR (1) | KR20150129718A (enExample) |
| CN (1) | CN105189548A (enExample) |
| AU (1) | AU2014241442B2 (enExample) |
| BR (1) | BR112015021979A2 (enExample) |
| CA (1) | CA2904644C (enExample) |
| CL (1) | CL2015002603A1 (enExample) |
| EA (1) | EA201591762A1 (enExample) |
| ES (1) | ES2898620T3 (enExample) |
| HK (1) | HK1220469A1 (enExample) |
| IL (1) | IL240769A0 (enExample) |
| MX (1) | MX369574B (enExample) |
| PH (1) | PH12015501865A1 (enExample) |
| SG (2) | SG11201506459PA (enExample) |
| WO (1) | WO2014159010A1 (enExample) |
| ZA (1) | ZA201506113B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013137686A1 (ko) * | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
| BR112015021979A2 (pt) | 2013-03-14 | 2017-08-29 | Regeneron Pharma | Anticorpos humanos para grem1 |
| BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
| IL263481B2 (en) * | 2016-06-14 | 2024-06-01 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| CN106399316B (zh) * | 2016-08-26 | 2019-03-01 | 西安交通大学第一附属医院 | 用于识别Gremlin-1的核酸适配子及其应用 |
| CN109641954A (zh) * | 2016-08-29 | 2019-04-16 | 里珍纳龙药品有限公司 | 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 |
| EP3554544A4 (en) | 2016-12-16 | 2020-07-29 | Bluefin Biomedicine, Inc. | ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| MA49273A (fr) | 2017-03-22 | 2020-02-05 | Bluefin Biomedicine Inc | Anticorps anti-tmeff1 et conjugués anticorps-médicament |
| US12161694B2 (en) * | 2017-03-24 | 2024-12-10 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| AU2019289176B2 (en) * | 2018-06-18 | 2026-02-19 | Adelaide university | Gremlin-1 antagonist for the prevention and treatment of cancer |
| WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| AU2020385991A1 (en) | 2019-11-21 | 2022-06-23 | Unity Biotechnology | Antibodies directed to Tie-2 and methods of use |
| EP4232475A1 (en) * | 2020-10-20 | 2023-08-30 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
| WO2022150654A2 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| AU2022207030A1 (en) * | 2021-01-18 | 2023-08-24 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
| KR20230156936A (ko) * | 2021-03-11 | 2023-11-15 | 상하이 지아오통 대학 | 그렘린1 길항제를 사용하여 질환을 치료하는 방법 |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| AU2023258146A1 (en) * | 2022-04-20 | 2024-09-05 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| TW202409078A (zh) * | 2022-07-18 | 2024-03-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | 穩定之包含抗gremlin1抗體的藥物製劑 |
| CN115786495A (zh) * | 2022-10-24 | 2023-03-14 | 杭州市第七人民医院 | 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途 |
| KR20250169623A (ko) * | 2023-04-13 | 2025-12-03 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | 암 치료를 위한 grem1 길항제를 수반하는 조합 요법 |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| WO1998033918A1 (en) | 1997-02-05 | 1998-08-06 | The Regents Of The University Of California | Morphogenic proteins |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1966725A (zh) | 2001-10-31 | 2007-05-23 | 爱尔康公司 | 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| EP1738767A1 (en) | 2001-10-31 | 2007-01-03 | Alcon, Inc. | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US20090041747A1 (en) | 2005-02-24 | 2009-02-12 | Novo Nordisk Health Care Ag | Compounds for Stabilizing Factor VII Polypeptide Formulations |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20090203041A1 (en) | 2006-04-21 | 2009-08-13 | Wei Shi | Bmp4 inhibitors |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US8383349B2 (en) | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| ATE530169T1 (de) | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| WO2013137686A1 (ko) | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | 그렘린-1에 대한 항체 |
| BR112015021979A2 (pt) | 2013-03-14 | 2017-08-29 | Regeneron Pharma | Anticorpos humanos para grem1 |
-
2014
- 2014-03-07 BR BR112015021979A patent/BR112015021979A2/pt not_active Application Discontinuation
- 2014-03-07 SG SG11201506459PA patent/SG11201506459PA/en unknown
- 2014-03-07 JP JP2016500767A patent/JP6581075B2/ja active Active
- 2014-03-07 CA CA2904644A patent/CA2904644C/en active Active
- 2014-03-07 HK HK16108451.7A patent/HK1220469A1/zh unknown
- 2014-03-07 CN CN201480014151.0A patent/CN105189548A/zh active Pending
- 2014-03-07 SG SG10201707518YA patent/SG10201707518YA/en unknown
- 2014-03-07 US US14/775,637 patent/US10377817B2/en active Active
- 2014-03-07 ES ES14713709T patent/ES2898620T3/es active Active
- 2014-03-07 AU AU2014241442A patent/AU2014241442B2/en active Active
- 2014-03-07 WO PCT/US2014/021471 patent/WO2014159010A1/en not_active Ceased
- 2014-03-07 MX MX2015011616A patent/MX369574B/es active IP Right Grant
- 2014-03-07 KR KR1020157024673A patent/KR20150129718A/ko not_active Withdrawn
- 2014-03-07 EP EP14713709.5A patent/EP2970448B1/en active Active
- 2014-03-07 EA EA201591762A patent/EA201591762A1/ru unknown
-
2015
- 2015-08-21 ZA ZA2015/06113A patent/ZA201506113B/en unknown
- 2015-08-23 IL IL240769A patent/IL240769A0/en unknown
- 2015-08-25 PH PH12015501865A patent/PH12015501865A1/en unknown
- 2015-09-11 CL CL2015002603A patent/CL2015002603A1/es unknown
-
2019
- 2019-05-08 JP JP2019087970A patent/JP2019151654A/ja active Pending
- 2019-06-27 US US16/454,663 patent/US11634480B2/en active Active
-
2023
- 2023-03-06 US US18/117,883 patent/US20230192831A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7440464B2 (ja) | 抗アクチビンａ抗体及びその使用 | |
| CN111133004B (zh) | 抗ctla-4抗体和其用途 | |
| CN106068275B (zh) | 抗pd-1的人抗体 | |
| EP2970448B1 (en) | Human antibodies to grem 1 | |
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| JP2020514310A5 (enExample) | ||
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| JP2017500018A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| HK1221409A1 (zh) | 抗ang2抗体和cd40激动剂的组合疗法 | |
| AU2020247175A1 (en) | Treatment employing anti-IL-13R antibody or binding fragment thereof | |
| JP2015503909A5 (enExample) | ||
| CN102027015A (zh) | 抗cxcr4抗体 | |
| RU2018129874A (ru) | Антитела против фактора свертывания xi | |
| JP2018501254A5 (enExample) | ||
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| JP2018529661A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| CN107406502A (zh) | 结合血管生成素2的抗体与结合编程性死亡配体1的抗体的组合疗法 | |
| AU2015264550B2 (en) | Ang2 antibodies | |
| JP2025509567A5 (enExample) | ||
| JP2018533588A (ja) | 治療パラダイム |